Physician profile
Johnny Perez
NPI 1184612467
$4,478.91
in general payments reported to CMS, 2019-2025
21 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.90 · 2020: $41.39 · 2021: $426 · 2022: $1,685 · 2023: $1,895 · 2024: $247 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,423 · Travel and Lodging: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.09 |
| Travel and Lodging | $867.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,811.93 | 2021-2025 | Ligasure, Signia, Sonicision |
| Redhill Biopharma INC. | $690.78 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Novo Nordisk INC | $180.57 | 2022-2023 | Wegovy, Saxenda |
| Intuitive Surgical, INC. | $140.43 | 2021-2024 | Da Vinci Surgical System |
| Endo Pharmaceuticals INC. | $140.18 | 2021-2024 | Nascobal |
| Smith+Nephew, INC. | $126.79 | 2022-2023 | Stravix, Grafix Pl |
| Ethicon US, LLC | $45.33 | 2021-2023 | Echelon; Endopath |
| Kowa Pharmaceuticals America, INC. | $42.05 | 2023 | Seglentis |
| Solventum Corporation | $34.58 | 2025 | Prevena |
| Tela Bio, INC. | $33.08 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Olympus America INC. | $30.74 | 2024 | Gastrointestinal Videoscope, Visera 4k Uhd Camera Control Unit |
| Asensus Surgical, INC. | $26.57 | 2024 | Senhance |
| Janssen Pharmaceuticals, INC | $25.00 | 2021 | |
| Reprise Biomedical, INC. | $22.25 | 2025 | Miro3d |
| Endogastric Solutions, INC | $22.19 | 2023 | Esophyx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $21.53 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.27 | 2020 | |
| Merck Sharp & Dohme LLC | $19.40 | 2023 | Keytruda, Lynparza |
| Innocoll Pharmaceuticals Limited | $17.34 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.37 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.